VPC
TYRA icon

Vestal Point Capital’s Tyra Biosciences TYRA Stock Holding History

Vestal Point Capital’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-54,000
Closed -$2.07M – 92
2026
Q1 		$2.07M Sell
54,000
-2,371,000
-98% -$76.8M 0.06% 85
2025
Q4 		$63.8M Hold
2,425,000
– – 2.17% 14
2025
Q3 		$33.9M Sell
2,425,000
-230,000
-9% -$2.62M 1.53% 24
2025
Q2 		$25.4M Sell
2,655,000
-224,829
-8% -$2.14M 1.34% 25
2025
Q1 		$26.8M Buy
2,879,829
+1,889,829
+191% +$24.5M 1.91% 18
2024
Q4 		$13.8M Buy
+990,000
New +$18M 0.82% 38

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vestal Point Capital's TYRA Position: Q2 2026 in Review

Vestal Point Capital sold out of Tyra Biosciences (TYRA) in Q2 2026, closing a stake of 54,000 shares — an estimated $2.07M sold.

Vestal Point Capital first reported a position in TYRA in Q4 2024 and held it in 6 quarters. The position peaked at $63.8M in Q4 2025. 169 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Vestal Point Capital reported no remaining Tyra Biosciences position as of Q2 2026 after selling out during the quarter.
  • Vestal Point Capital sold 54,000 Tyra Biosciences shares in Q2 2026, an estimated $2.07M.
  • Vestal Point Capital first reported a position in Tyra Biosciences in Q4 2024 and held it in 6 quarters.
  • Vestal Point Capital's Tyra Biosciences position peaked at $63.8M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.